Mend (Pharmaceuticals and Biotechnology)

Website
Current Valuation
$63.5M
As of December 4, 2025
Total Funding Raised
$26.3M
Last Round
Later Stage VC

$20.4M

Last Funding
Dec 2025

Funding date

Capital Efficiency
2.41x

Valuation / Funding

Funding History & Valuation Timeline
Complete history of all funding rounds and valuation milestones

No funding history available

Funding data has not been imported for this company yet

Valuation Analysis

Current Valuation Metrics

Mend (Pharmaceuticals and Biotechnology) is currently valued at $63.5M as of December 4, 2025. The company has raised a total of $26.3M in funding.

Capital Efficiency

With a capital efficiency ratio of 2.41x, Mend (Pharmaceuticals and Biotechnology) has achieved a valuation that is 2.41 times the total capital raised.

Track Mend (Pharmaceuticals and Biotechnology) Valuation Updates

Get notified when Mend (Pharmaceuticals and Biotechnology) raises new funding or valuation changes

Explore More Data
Detailed analysis for Mend (Pharmaceuticals and Biotechnology)

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Mend (Pharmaceuticals and Biotechnology)'s valuation history, funding rounds, and growth metrics.

No credit card required

What is Mend (Pharmaceuticals and Biotechnology) Worth in 2026?

Mend (Pharmaceuticals and Biotechnology) is a leading private company in the technology sector. Track Mend (Pharmaceuticals and Biotechnology)'s valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Mend (Pharmaceuticals and Biotechnology) Valuation is Determined

Private company valuations like Mend (Pharmaceuticals and Biotechnology)'s are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.